Related references
Note: Only part of the references are listed.Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer
Jacqueline Vuky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
Damian Wild et al.
CANCER RESEARCH (2011)
Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
Barry J. Allen
IMMUNOTHERAPY (2011)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Bevacizumab andWeekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Filippo Francini et al.
PROSTATE CANCER (2011)
Future Prospects for Targeted Alpha Therapy
Barry J. Allen
CURRENT RADIOPHARMACEUTICALS (2011)
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment
Cecile Ortholan et al.
EUROPEAN JOURNAL OF CANCER (2010)
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models BY 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Yong Li et al.
CLINICAL CANCER RESEARCH (2009)
Preparation and testing of bevacizumab radioimmunoconjugates with bismuth-213 and bismuth-205/bismuth-206
Syed M. Abbas Rizvi et al.
CANCER BIOLOGY & THERAPY (2008)
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
Bhuvaneswari Ramaswamy et al.
CLINICAL CANCER RESEARCH (2006)
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters
YJ Song et al.
CANCER LETTERS (2006)
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer
CF Qu et al.
CLINICAL & EXPERIMENTAL METASTASIS (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
BJ Allen et al.
BRITISH JOURNAL OF CANCER (2003)
In vitro cytotoxicity of bismuth-213 (Bi-213)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells
M Ranson et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Share Paper
